

## 1.0.7 DOC EIA

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## EQUALITY IMPACT ASSESSMENT

### Headaches

#### 3.0 Guideline development: before consultation (to be completed by the developer before draft guideline consultation)

3.1 Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

n/a

3.2 Have any **other** potential equality issues (in addition to those identified during the scoping process) been identified, and, if so, how has the Committee addressed them?

No equality issues identified

3.3 Were the Committee's considerations of equality issues described in the consultation document, and, if so, where?

n/a

## 1.0.7 DOC EIA

3.4 Do the preliminary recommendations make it more difficult in practice for a specific group to access services compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

Topiramate is teratogenic, so cannot be used in pregnancy or for women who may become pregnant. This could make it difficult for women of child bearing age to access prophylactic treatment for migraine, so the committee took this into account and made the recommendation that either topiramate or propranolol should be offered as a first line treatment. The committee highlighted the teratogenicity of topiramate in the recommendation as they felt that this was an important consideration when offering prophylactic medication, and recommended that women of child bearing age who are offered topiramate should also be offered contraception if needed.

We also specified pregnant women as a subgroup in the protocol, but we didn't find any evidence for this group.

3.5 Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

3.6 Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access to services identified in questions 3.1, 3.2 or 3.3, or otherwise fulfil NICE's obligation to advance equality?

No

## 1.0.7 DOC EIA